Treatment of atopic dermatitis in pregnancy

Dermatologic Therapy

Volumn 26, Issue 4, 2013, Pages 293-301

  Babalola, Olubukola ^a   Strober, Bruce E ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; Eczema; Lactation; Medication safety; Pregnancy

Indexed keywords

ACICLOVIR; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CEPHALOSPORIN DERIVATIVE; CHLORPHENIRAMINE; CORTICOSTEROID; CYCLOSPORIN; DICLOXACILLIN; DIPHENHYDRAMINE; EMOLLIENT AGENT; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; FEXOFENADINE; HYDROXYZINE; LORATADINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXACILLIN; PENICILLIN DERIVATIVE; PSEUDOMONIC ACID; PSORALEN; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BREAST FEEDING; BREAST MILK; CENTRAL NERVOUS SYSTEM DISEASE; CLEFT PALATE; CONCURRENT INFECTION; CRANIOFACIAL MALFORMATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; FEMALE; FOLIC ACID BLOOD LEVEL; GRAFT RECIPIENT; GROWTH DISORDER; HISTOPATHOLOGY; HUMAN; HYDRATION; INFECTION RISK; KAPOSI VARICELLIFORM ERUPTION; LACTATION; LEUKOPENIA; LIMB DISEASE; LOW BIRTH WEIGHT; MATERNAL SERUM; MATERNAL TREATMENT; MILK PRODUCTION; MUTAGENESIS; ORGAN TRANSPLANTATION; PANCREATITIS; PANCYTOPENIA; PHOTOTHERAPY; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; SPONTANEOUS ABORTION; TERATOGENESIS; TERATOGENICITY;

ATOPIC DERMATITIS; ECZEMA; LACTATION; MEDICATION SAFETY; PREGNANCY;

ADRENAL CORTEX HORMONES; CYCLOSPORINE; DERMATITIS, ATOPIC; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; PHOTOTHERAPY; PREGNANCY; PREGNANCY COMPLICATIONS; TACROLIMUS;

EID: 84885220651     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12074     Document Type: Article

References (85)

1. Koutroulis I, Papoutsis J, Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. ObstetGynecol Surv 2011: 66 (10): 654-663.
2. Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective twocenter study on 505 pregnant patients. J AmAcad Dermatol 2006: 54 (3): 395-404.
3. Ingber A. Atopic eruption of pregnancy. J Eur Acad Dermatol Venereol 2010: 24 (8): 984.
4. Vaughan Jones SA,Hern S,Nelson-Piercy C, et al. A prospective study of 200 women with dermatoses of pregnancy correlating the clinical findings with hormonal and immunopathological profiles. Br J Dermatol 1999: 141: 71-81.
5. Cohen LM, Kroumpouzos G. Pruritic dermatoses of pregnancy: to lump or to split? J Am Acad Dermatol 2007: 56: 708-709.
6. Cho S, Kim HJ, Oh SH, Park CO, Jung JY, Lee KH. The influence of pregnancy and menstruation on the deterioration of atopic dermatitis symptoms. Ann Dermatol 2010: 22 (2): 180-185.
7. Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol 1991: 125: 59-61.
8. Weatherhead S, Robson SC, Reynolds NJ. Eczema in pregnancy. BMJ 2007: 335: 152-154.
9. Kang K, Poster AM, Nedorost ST, Steven SR, Cooper KD. Atopic dermatitis. In: Bolognia JL, Jorizzo JL, Rapini RP, et al, eds. Dermatology. NewYork: Mosby, 2003: 199-214.
10. Wilder RL. Hormones, pregnancy, and autoimmune disease. Ann N Y Acad Sci 1998: 840: 45-50.
11. Akdis M, Trautmann A, Klunker S, Blaser K, Akdis CA. T cells and effector functions in atopic dermatitis. Curr Allergy Asthma Rep 2002: 2: 1-3.
12. Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003: 49: 1088-1095.
13. Parcels DA. Women's mental health nursing: depression, anxiety and stress during pregnancy. J Psychiatr Ment Health Nurs 2010: 17: 813-820.
14. Chen W,Mempel M, Schober W, Behrendt H, Ring J. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 2008: 63: 1418-1427.
15. Leung DY, Eichenfield LF, Boguniewicz M. Chapter 14. Atopic dermatitis (atopic eczema). In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Dallas NA, eds. Fitzpatrick's dermatology in general medicine, 8th ed. New York: McGraw-Hill, 2012.
16. Papadakis MA, McPhee SJ, Rabow MW. Chapter 6. Dermatologic disorders. In: Papadakis MA, McPhee SJ, Rabow MW, eds. Current medical diagnosis & treatment. New York: McGraw-Hill Professional Publishing, 2013.
17. Brown KD, Banuchi V, Selesnick SH. Chapter 47. Diseases of the external ear. In: Lalwani AK, ed. Current diagnosis & treatment in otolaryngology - head & neck surgery, 3rd ed. New York: McGraw-Hill, 2012.
18. Edwards MJ, Agho K, Attia J, et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids. Am J Med Genet 2003: 120A: 459-463.
19. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997: 56 (5): 335-340.
20. Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007: 197 (6): 585.e1-585.e7.
21. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002: 81 (3): 234-239.
22. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011: 183 (7): 796-804.
23. Chi C-C, Kirtschig G, Aberer W, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011: 165 (5): 943-952.
24. Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother 2012: 3 (2): 105-108.
25. Saxén I. Letter: cleft palate and maternal diphenhydramine intake. Lancet 1974: 1 (7854): 407-408.
26. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation, 5th ed. Baltimore: Williams &Wilkins, 1998.
27. Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997: 78 (2): 157-159.
28. Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008: 26: 19-23.
29. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002: 11: 146-152.
30. Gilbert C, Mazzotta P, Loebstein R, Koren G. Fetal safety of drugs used in the treatment of allergic rhinitis: a critical review. Drug Saf 2005: 28: 707-719.
31. Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003: 111: 1239-1243.
32. Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003: 111: 479-483.
33. Kallen B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 2006: 3: 106-107.
34. Schwarz EB, Moretti ME, Nayak S, Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf 2008: 31: 775-788.
35. Lione A, Scialli AR. The developmental toxicity of the H1 histamine antagonists. Reprod Toxicol 1996: 10: 247-255.
36. Serreau R, Komiha M, Blanc F, Guillot F, Jacqz-Aigrain E. Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. Reprod Toxicol 2005: 20: 573-574.
37. Brost BC, Scardo JA, Newman RB. Diphenhydramine overdose during pregnancy: lessons from the past. Am J Obstet Gynecol 1996: 175: 1376-1377.
38. Hara GS, Carter RP, Krantz KE. Dramamine in labor: potential boon or a possible bomb? J Kans Med Soc 1980: 81: 134-136,55.
39. Zierler S, Purohit D. Prenatal antihistamine exposure and retrolental fibroplasia. Am J Epidemiol 1986: 123: 192-196.
40. So M, Bozzo P, Inoue M, Einarson A. Safety of antihistamines during pregnancy and lactation. Can Fam Physician 2010: 56 (5): 427-429.
41. LactMed: Drugs and Lactation Database. A peer-reviewed and fully referenced database of drugs to which breastfeeding. 2012.
42. Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N-desmethyldoxepin in breast milk. Lancet 1985: 2 (8464): 1124.
43. Frey OR, Scheidt P, von Brenndorff AI. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. Ann Pharmacother 1999: 33 (6): 690-693.
44. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012: 24 (3): 253-260.
45. Darsow U, Wollenberg A, Simon D, et al. European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010: 24: 317-328.
46. Dotterud LK,Wilsgaard T, Vorland LH, Falk ES. The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls. Int J Circumpolar Health 2008: 67: 254-260.
47. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008: 59 (2): 295-315.
48. Gudjonsson JE, Elder JT. Chapter 18. Psoriasis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Dallas NA, eds. Fitzpatrick's dermatology in general medicine, 8th ed. New York: McGraw-Hill, 2012.
49. Park KK,Murase JE.Narrowband UV-B phototherapy during pregnancy and folic acid depletion. Arch Dermatol 2012: 148 (1): 132-133.
50. Gabbe SG. Drug therapy in autoimmune disease. Clin Obstet Gynecol 1987: 26: 635-641.
51. Chin SO, Brodsky NL, Bhandari V. Antenatal steroid use is associated with increased gastroesophageal reflux in neonates. Am J Perinatol 2003: 20 (4): 205-213.
52. Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl JMed 2007: 357 (12): 1190-1198.
53. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004: 18 (1): 93-101.
54. Crowther CA, Doyle LW, Haslam RR, et al. Outcomes at 2 years of age after repest doses of antenatal corticosteroids. N Engl J Med 2007: 357: 1179-1189.
55. Schmand B, Neuvel J, Smolders-de Haas H, Hoeks J, Treffers PE, Koppe JG. Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics 1990: 86 (1): 58-64.
56. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000: 62 (6): 385-392.
57. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993: 53: 324-328.
58. McKenzie SA, Selley JA, Agnew JE. Secretion of prednisolone into breast milk. Arch Dis Child 1975: 50: 894-896.
59. Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health (Lond Engl) 2010: 6 (3): 431-440.
60. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005: 35 (2): 112-121.
61. Bae YS, Van Voorhees AS, Hsu S, et al. National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from theMedical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012: 67 (3): 459-477.
62. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000: 70 (12): 1718-1721.
63. Jain AB, Reyes J,Marcos A, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 2003: 76 (5): 827-832.
64. Gardiner SJ, Begg EJ. Breastfeeding during tacrolimus therapy. Obstet Gynecol 2006: 107 (2 Pt 2): 453-455.
65. Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation 1998: 65: 253-255.
66. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010: 63 (6): 949-972.
67. Armenti VT, Ahlswede KM, Ahlswede BA, et al. Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1995: 59: 476-479.
68. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001: 71: 1051-1055.
69. Armenti VT,McGrory CH, Cater JR, Radomski JS,Moritz MJ. Pregnancy outcomes in female renal transplant recipients. Transplant Proc 1998: 30 (5): 1732-1734.
70. Lamarque V, Leleu MF, Monka C, Krupp P. Analysis of 629 pregnancy outcomes in renal transplant recipients with Sandimmune. Transplant Proc 1997: 29: 2480.
71. Stanley CW, Gottlieb R, Zager R, et al. Developmental wellbeing in offspring of women receiving cyclosporine postrenal transplant. Transplant Proc 1999: 31: 241-242.
72. Montnemery P, Nihlen U, Goran Lofdahl C, Nyberg P, Svensson A. Prevalence of self-reported eczema in relation to living environment, socio-economic status and respiratory symptoms assessed in a questionnaire study. BMC Dermatol 2003: 3:4.
73. Tendron A, Gouyon JB, Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 2002: 17: 121-130.
74. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000: 160: 610-619.
75. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the national transplantation pregnancy registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2004: 103-114.
76. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985: 92: 233-239.
77. Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012: 35 (5): 501-515.
78. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011: 165 (4): 711-734.
79. Hyoun SC, Obic?an SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol 2012: 94 (4): 187-207.
80. Stern RS, Lange R. Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis. Arch Dermatol 1997: 127: 347-350.
81. Gunnarskog JG, Kallen AJ, Lindelof BG, Sigurgeirsson B. Psoralen photochemotherapy (PUVA) and pregnancy. Arch Dermatol 1993: 129: 320-323.
82. McCall CO. Chapter 52. Eczema, psoriasis, cutaneous infections, acne, and other common skin disorders. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison's principles of internal medicine, 18th ed. New York: McGraw-Hill, 2012.
83. Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther 2006: 44 (2): 57-63.
84. Papadakis MA, McPhee SJ, Rabow MW. Chapter 6. dermatologic disorders. In: Papadakis MA, McPhee SJ, Rabow MW, eds. Current medical diagnosis & treatment 2013. New York: McGraw-Hill, 2013.
85. Drake AL, Roxby AC, Kiarie J, et al. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial. PLoS One 2012: 7 (4): e34635.